A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)
Copyright © 2023 Elsevier España, S.L.U. All rights reserved..
BACKGROUND: The response to SARS-CoV-2 vaccination decreases in inflammatory bowel disease (IBD) patients, specially under anti-TNF treatment. However, data on medium-term effectiveness are limited, specially using new recommended seroconversion rate (>260BAU/mL). Our aim was to evaluate the 6-month>260 BAU-seroconversion rate after full vaccination and after booster-dose.
METHODS: VACOVEII is a Spanish multicenter, prospective study promoted by GETECCU. IBD patients full vaccinated against SARS-CoV-2 and without previous COVID-19 infection, treated or not with immunosuppressants, were included. The booster dose was administered 6 months after the full vaccination. Seroconversion was set at 260BAU/mL, according to most recent recommendations and was assessed 6 months after the full vaccination and 6 months after booster-dose.
RESULTS: Between October 2021 and March 2022, 313 patients were included (124 no treatment or mesalazine; 55 immunomodulators; 87 anti-TNF; 19 anti-integrin; and 28 ustekinumab). Most patients received mRNA-vaccines (86%). Six months after full vaccination, overall seroconversion rate was 44.1%, being significantly lower among patients on anti-TNF (19.5%, p<0.001) and ustekinumab (35.7%, p=0.031). The seroconversion rate after booster was 92%. Again, anti-TNF patients had a significantly lower seroconversion rate (67%, p<0.001). mRNA-vaccine improved seroconversion rate (OR 11.720 [95% CI 2.26-60.512]).
CONCLUSION: The full vaccination regimen achieves suboptimal response in IBD patients, specially among those anti-TNF or ustekinumab. The booster dose improves seroconversion rate in all patients, although it remains limited in those treated with anti-TNF. These results reinforce the need to prioritize future booster doses in patients on immunosuppressants therapy, specially under anti-TNF, and using mRNA-vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Gastroenterologia y hepatologia - (2023) vom: 23. Nov. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Anti-TNF |
|---|
| Anmerkungen: |
Date Revised 15.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.gastrohep.2023.11.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364983701 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364983701 | ||
| 003 | DE-627 | ||
| 005 | 20231227132654.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gastrohep.2023.11.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1229.xml |
| 035 | |a (DE-627)NLM364983701 | ||
| 035 | |a (NLM)38007154 | ||
| 035 | |a (PII)S0210-5705(23)00474-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Casas Deza, Diego |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a BACKGROUND: The response to SARS-CoV-2 vaccination decreases in inflammatory bowel disease (IBD) patients, specially under anti-TNF treatment. However, data on medium-term effectiveness are limited, specially using new recommended seroconversion rate (>260BAU/mL). Our aim was to evaluate the 6-month>260 BAU-seroconversion rate after full vaccination and after booster-dose | ||
| 520 | |a METHODS: VACOVEII is a Spanish multicenter, prospective study promoted by GETECCU. IBD patients full vaccinated against SARS-CoV-2 and without previous COVID-19 infection, treated or not with immunosuppressants, were included. The booster dose was administered 6 months after the full vaccination. Seroconversion was set at 260BAU/mL, according to most recent recommendations and was assessed 6 months after the full vaccination and 6 months after booster-dose | ||
| 520 | |a RESULTS: Between October 2021 and March 2022, 313 patients were included (124 no treatment or mesalazine; 55 immunomodulators; 87 anti-TNF; 19 anti-integrin; and 28 ustekinumab). Most patients received mRNA-vaccines (86%). Six months after full vaccination, overall seroconversion rate was 44.1%, being significantly lower among patients on anti-TNF (19.5%, p<0.001) and ustekinumab (35.7%, p=0.031). The seroconversion rate after booster was 92%. Again, anti-TNF patients had a significantly lower seroconversion rate (67%, p<0.001). mRNA-vaccine improved seroconversion rate (OR 11.720 [95% CI 2.26-60.512]) | ||
| 520 | |a CONCLUSION: The full vaccination regimen achieves suboptimal response in IBD patients, specially among those anti-TNF or ustekinumab. The booster dose improves seroconversion rate in all patients, although it remains limited in those treated with anti-TNF. These results reinforce the need to prioritize future booster doses in patients on immunosuppressants therapy, specially under anti-TNF, and using mRNA-vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-TNF | |
| 650 | 4 | |a Enfermedad inflamatoria intestinal | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccination | |
| 650 | 4 | |a Vacuna | |
| 700 | 1 | |a Julián Gomara, Ana Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Caudevilla Biota, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Beltrán, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Domènech, Eugeni |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez Casbas, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Mañosa, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Zabana, Yamile |e verfasserin |4 aut | |
| 700 | 1 | |a Roc Alfaro, Lourdes |e verfasserin |4 aut | |
| 700 | 1 | |a Valverde Romero, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a García González, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Sicilia, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Laredo, Viviana |e verfasserin |4 aut | |
| 700 | 1 | |a Alcalá Escriche, Maria José |e verfasserin |4 aut | |
| 700 | 1 | |a Madero Velázquez, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreiro-Iglesias, Rocío |e verfasserin |4 aut | |
| 700 | 1 | |a Palmero Pérez, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Calafat, Margalida |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio Iturria, Saioa |e verfasserin |4 aut | |
| 700 | 1 | |a Moraleja Yudego, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Ber Nieto, Yolanda |e verfasserin |4 aut | |
| 700 | 1 | |a García Mateo, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a P Gisbert, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Vicente Lidón, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Arias, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Alfambra, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Doñate Borao, Ana Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Peña González, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Corsino Roche, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Vicuña Arregui, Miren |e verfasserin |4 aut | |
| 700 | 1 | |a Elorza, Ainara |e verfasserin |4 aut | |
| 700 | 1 | |a Domínguez Cajal, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Chaparro, María |e verfasserin |4 aut | |
| 700 | 1 | |a Barreiro-de Acosta, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a García-López, Santiago |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterologia y hepatologia |d 1993 |g (2023) vom: 23. Nov. |w (DE-627)NLM075187280 |x 0210-5705 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:23 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gastrohep.2023.11.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 23 |c 11 | ||